Zurich-Schlieren, Switzerland, 7 September 2023
We are thrilled to announce that TOPADUR Pharma AG has once again been recognized as one of Switzerland's top 25 scale-up companies.
This achievement is a demonstration to our team's dedication and our partners' support.
We are grateful for this recognition and remain committed to pushing the boundaries of innovation in the years to come.
Please check out the link below.
We are proud to be recognized as one of Switzerland's most promising scale-ups in 2023.
Read moreTOPADUR announced that Pascal Brenneisen has been appointed CEO, effective April 1, 2023, on top of his Board member assignment.
Read morePulmonary fibrosis is a chronic and usually fatal disease. The project will investigate the anti-fibrotic effects of TOP-V122.
Read more